GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Winston Pharmaceuticals Inc (GREY:WPHM) » Definitions » Asset Turnover

Winston Pharmaceuticals (Winston Pharmaceuticals) Asset Turnover : 0.25 (As of Mar. 2010)


View and export this data going back to 2006. Start your Free Trial

What is Winston Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Winston Pharmaceuticals's Revenue for the three months ended in Mar. 2010 was $0.32 Mil. Winston Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2010 was $1.26 Mil. Therefore, Winston Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2010 was 0.25.

Asset Turnover is linked to ROE % through Du Pont Formula. Winston Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2010 was -665.70%. It is also linked to ROA % through Du Pont Formula. Winston Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2010 was -146.47%.


Winston Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Winston Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Winston Pharmaceuticals Asset Turnover Chart

Winston Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Dec08 Dec09
Asset Turnover
- - - 0.09 0.37

Winston Pharmaceuticals Quarterly Data
Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.10 0.12 0.16 0.25

Competitive Comparison of Winston Pharmaceuticals's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Winston Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Winston Pharmaceuticals's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Winston Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Winston Pharmaceuticals's Asset Turnover falls into.



Winston Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Winston Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2009 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2009 )/( (Total Assets (A: Dec. 2008 )+Total Assets (A: Dec. 2009 ))/ count )
=1.395/( (5.791+1.676)/ 2 )
=1.395/3.7335
=0.37

Winston Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2010 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2010 )/( (Total Assets (Q: Dec. 2009 )+Total Assets (Q: Mar. 2010 ))/ count )
=0.317/( (1.676+0.842)/ 2 )
=0.317/1.259
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Winston Pharmaceuticals  (GREY:WPHM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Winston Pharmaceuticals's annulized ROE % for the quarter that ended in Mar. 2010 is

ROE %**(Q: Mar. 2010 )
=Net Income/Total Stockholders Equity
=-1.844/0.277
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1.844 / 1.268)*(1.268 / 1.259)*(1.259/ 0.277)
=Net Margin %*Asset Turnover*Equity Multiplier
=-145.43 %*1.0071*4.5451
=ROA %*Equity Multiplier
=-146.47 %*4.5451
=-665.70 %

Note: The Net Income data used here is four times the quarterly (Mar. 2010) net income data. The Revenue data used here is four times the quarterly (Mar. 2010) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Winston Pharmaceuticals's annulized ROA % for the quarter that ended in Mar. 2010 is

ROA %(Q: Mar. 2010 )
=Net Income/Total Assets
=-1.844/1.259
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-1.844 / 1.268)*(1.268 / 1.259)
=Net Margin %*Asset Turnover
=-145.43 %*1.0071
=-146.47 %

Note: The Net Income data used here is four times the quarterly (Mar. 2010) net income data. The Revenue data used here is four times the quarterly (Mar. 2010) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Winston Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Winston Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Winston Pharmaceuticals (Winston Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
100 North Fairway Drive, Suite 134, Vernon Hills, IL, USA, 60061
Winston Pharmaceuticals Inc is a pharmaceutical company, which is engaged in the discovery and development of products for pain management. The company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Subbarao V Uppaluri director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Glenn L Halpryn director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Steven Jerry Glauser 10 percent owner 1428 BRICKELL AVENUE, SUITE 105, MIAMI FL 33131
Noah M Silver director, officer: Vice President 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Alan Jay Weisberg director, officer: Chief Financial Officer 2500 NORTH MILITARY TRAIL, SUITE 206, BOCA RATON FL 33431
Stephen Bittel 10 percent owner 4400 BISCAYNE BOULEVARD SUITE 950 MIAMI FL 33137

Winston Pharmaceuticals (Winston Pharmaceuticals) Headlines

No Headlines